Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine attacks. Pharmaceutical laboratories require high-quality reference standards of… Read more

![Chemical structure of (R)-1'-(tert-Butyl)-3-chloro-5,7-dihydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1456803-73-8-R-1-tert-Butyl-3-chloro-57-dihydrospirocyclopentabpyridine-63-pyrrolo23-bpyridin-21H-one.png&w=3840&q=75)
![Chemical structure of (R)-1'-(tert-Butyl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2408280-92-0-R-1-tert-Butyl-57-dihydrospirocyclopentabpyridine-63-pyrrolo23-bpyridin-21H-one.png&w=3840&q=75)
![Chemical structure of (R)-2'-Oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2568065-21-2-R-2-Oxo-1257-tetrahydrospirocyclopentabpyridine-63-pyrrolo23-bpyridine-3-carboxylic-Acid.png&w=3840&q=75)
![Chemical structure of (S)-1'-(tert-Butyl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1455358-16-3-S-1-tert-Butyl-2-oxo-1257-tetrahydrospirocyclopentabpyridine-63-pyrrolo23-bpyridine-3-carboxylic-Acid.png&w=3840&q=75)
![Chemical structure of (S)-1'-(tert-Butyl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2408280-91-9-S-1-tert-Butyl-57-dihydrospirocyclopentabpyridine-63-pyrrolo23-bpyridin-21H-one.png&w=3840&q=75)
![Chemical structure of (S)-2'-Oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1375541-21-1-S-2-Oxo-1257-tetrahydrospirocyclopentabpyridine-63-pyrrolo23-bpyridine-3-carboxylic-Acid.png&w=3840&q=75)
![Chemical structure of (S)-5,7-Dihydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FS-57-Dihydrospirocyclopentabpyridine-63-pyrrolo23-bpyridin-21H-one.png&w=3840&q=75)
![Chemical structure of 1-(tert-Butyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1455358-06-1-1-tert-Butyl-13-dihydro-2H-pyrrolo23-bpyridin-2-one.png&w=3840&q=75)
![Chemical structure of 1-(tert-Butyl)-3-((5-chloro-2-(hydroxymethyl)pyridin-3-yl)methyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F3133197-89-1-1-tert-Butyl-3-5-chloro-2-hydroxymethylpyridin-3-ylmethyl-13-dihydro-2H-pyrrolo23-bpyridin-2-one.png&w=3840&q=75)


















Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine attacks. Pharmaceutical laboratories require high-quality reference standards of Ubrogepant to support rigorous analytical testing and quality control processes. This category includes the active pharmaceutical ingredient alongside a comprehensive range of related compounds, such as synthetic impurities, degradation products, and stable isotope labelled compounds. These materials are essential for accurate impurity profiling, allowing researchers to identify and quantify potential byproducts that may arise during manufacturing or storage. By utilizing these characterized standards, analytical chemists can perform robust method validation and stability studies that align with ICH guidelines and pharmacopeial requirements. Ensuring the availability of these specific reference materials is critical for maintaining the safety, efficacy, and regulatory compliance of pharmaceutical development and testing programs.